OncoMatch/Clinical Trials/NCT07053072
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
Is NCT07053072 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Low Dose PD-1 mRNA LNP Vaccine and Medium dose PD-1 mRNA LNP vaccines for liver cancer.
Treatment: Low Dose PD-1 mRNA LNP Vaccine · Medium dose PD-1 mRNA LNP vaccines · High dose PD-1 mRNA LNP vaccines — Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard therapy — second-line
has failed second-line standard therapy
Cannot have received: mRNA drug
Patients who have been inoculated with mRNA drugs
Cannot have received: lipid nanoparticle drug
Participation in clinical trials involving lipid nanoparticles, a component of the study vaccine
Cannot have received: other investigational drug
Participation in a clinical trial of another drug within 4 weeks
Lab requirements
Blood counts
hemoglobin ≥80g/L (no blood transfusion within 14 days); neutrophil count >1.5×10^9 /L; platelet count ≥80×10^9 /L
Kidney function
endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula)
Liver function
total bilirubin ≤1.5 × ULN; ALT or AST ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN
Cardiac function
left ventricular ejection fraction (LVEF) ≥50%
Good function of major organs, i.e., relevant examination indexes within 14 days prior to randomization meet the following requirements: Routine blood tests: hemoglobin ≥80g/L (no blood transfusion within 14 days); neutrophil count >1.5×10^9 /L; platelet count ≥80×10^9 /L; Biochemical tests: total bilirubin ≤1.5 × ULN (upper limit of normal); blood alanine aminotransferase (ALT) or blood alanine transaminase (AST) ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN; endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula); cardiac Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07053072 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mRNA drug, lipid nanoparticle drug, other investigational drug disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages